Stay updated on KN035 Anti-PD-L1 Clinical Trial
Sign up to get notified when there's something new on the KN035 Anti-PD-L1 Clinical Trial page.

Latest updates to the KN035 Anti-PD-L1 Clinical Trial page
- Check5 days agoChange DetectedThe page now displays a new revision tag (v3.6.2) replacing the previous v3.6.0, representing a minor update to the page's documentation/metadata.SummaryDifference0.1%

- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedEnrollment is now shown as closed, indicating recruitment has ended. The page also adds new help/navigation sections (How to Read a Study Record, Common Questions, How to Join a Study) and updates the Intervention/Treatment heading along with a revision tag.SummaryDifference0.5%

- Check26 days agoChange DetectedThe page revision tag changed from v3.5.4 to v3.5.5, indicating a newer revision of the page content.SummaryDifference0.1%

- Check40 days agoChange DetectedNo textual changes are detected in the provided change set for this page. The page content remains as shown in the current context.SummaryDifference0.1%

- Check48 days agoChange DetectedThe page now shows Revision: v3.5.4, replacing the previous v3.5.3. This indicates a minor deployment update to the page or platform with no visible content changes.SummaryDifference0.1%

- Check55 days agoChange DetectedA new publication citation was added under Publications. It references a 2024 Oncologist article about envafolimab (PD-L1 antibody) in advanced solid tumors.SummaryDifference0.1%

Stay in the know with updates to KN035 Anti-PD-L1 Clinical Trial
Enter your email address, and we'll notify you when there's something new on the KN035 Anti-PD-L1 Clinical Trial page.